Generic Medicine Info
Should be taken with food. Take w/ main meals or w/ a glass of milk.
Hyperlipidaemia. Severe hepatic and renal impairment. Pregnancy and lactation. Concomitant use w/ methotrexate, tetracyclines, vit A or other retinoids, low dose progesterone-only products (minipills).
Special Precautions
Females of reproductive potential. Patient Counselling Avoid exposure to natural or artificial sunlight. This drug may decrease night vision, if affected, do not drive or operate any vehicle. Avoid blood donation during therapy or at least 1-3 yr after stopping therapy. Monitoring Parameters Monitor plasma lipid, glucose levels (esp in diabetics patients) regularly; bone abnormalities (long-term use). Perform LFTs; pregnancy tests (2 negative tests prior to therapy, mthly during treatment and 3 mthly for 3 yr after stopping therapy).
Adverse Reactions
Cheilitis, alopecia, skin peeling, rhinitis, dry skin, nail disorder, pruritus, rigors, xerophthalmia, dry mouth, epistaxis, arthralgia, spinal hyperostosis, rash, hyperaesthesia, paraesthesia, paronychia, skin atrophy, decreased night vision, abdominal pain; abnormal hair texture; dermatitis; diarrhoea; epidermal fragility; erythema; headache; myalgia; nausea, vomiting; peripheral oedema; psudomotor cerebri, depression and other psychiatric symptoms (e.g. aggressive feelings, suicidal thoughts); increased liver enzymes, uric acid, BUN, triglycerides and cholesterol levels; increased or decreased electrolytes, haematocrit, Hb, glucose.
Potentially Fatal: Hepatotoxicity, fulminant pancreatitis.
Drug Interactions
May reduce the protein binding of phenytoin.
ATC Classification
D05BB02 - acitretin ; Belongs to the class of systemic retinoids used in the treatment of psoriasis.
Disclaimer: This information is independently developed by CIMS based on acitretin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in